What is Edwards Lifesciences?
Structural heart medical devices company with $4.5B 2025 TAVR sales revenue scale and public-market buying capacity.
- Category
- Structural heart medical devices
- Headquarters
- Irvine, CA
- Founded
- 1958
- Employees
- 19,000+
- Total funding
- Public company; no VC funding
- Status
- NYSE: EW; Public company
What is Edwards Lifesciences?
Edwards Lifesciences is a public structural heart medical devices company headquartered in Irvine, CA. Edwards reported full-year 2025 TAVR sales of $4.5 billion and continued to emphasize structural heart innovation after its critical-care separation.
Edwards Lifesciences operates in structural heart medical devices with a portfolio that includes SAPIEN TAVR valves, EVOQUE, PASCAL, Surgical heart valves. Edwards reported full-year 2025 TAVR sales of $4.5 billion and continued to emphasize structural heart innovation after its critical-care separation. The company employs about 19,000+ and trades as NYSE: EW, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Edwards Lifesciences through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, Edwards Lifesciences is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does Edwards Lifesciences offer?
Edwards Lifesciences offers products and services across SAPIEN TAVR valves, EVOQUE, PASCAL, Surgical heart valves and related healthcare workflows.
- SAPIEN TAVR valves· Transcatheter aortic valve replacement
- EVOQUE· Tricuspid valve replacement
- PASCAL· Transcatheter repair
- Surgical heart valves· Surgery
- Structural heart failure pipeline· Pipeline
- Aortic regurgitation programs· Pipeline
How does Edwards Lifesciences make money?
Edwards Lifesciences earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
Edwards Lifesciences earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $4.5B 2025 TAVR sales of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Edwards Lifesciences improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads Edwards Lifesciences?
Edwards Lifesciences is led by Bernard Zovighian, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Bernard ZovighianChief Executive OfficerCEO since 2023Leads Edwards as a focused structural-heart company.
- Scott UllemChief Financial OfficerCFO through planned 2026 transitionOversees finance and capital allocation.
- Larry WoodCorporate Vice President, Transcatheter Aortic Valve ReplacementBusiness-unit leaderLeads the core TAVR franchise.
- Daveen ChopraCorporate Vice President, Transcatheter Mitral and Tricuspid TherapiesBusiness-unit leaderLeads TMTT growth.
How do you contact Edwards Lifesciences's leadership?
Edwards Lifesciences publishes official Edwards investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
official Edwards investor-relations contact route; personal executive email format not verified- Larry WoodCorporate Vice President, Transcatheter Aortic Valve Replacementofficial Edwards investor-relations contact route
How much funding has Edwards Lifesciences raised?
Edwards Lifesciences is a mature public company, not a venture-backed startup. It trades as NYSE: EW and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
Edwards Lifesciences's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is NYSE: EW, $4.5B 2025 TAVR sales of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: Edwards Lifesciences has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did Edwards Lifesciences get here?
Edwards Lifesciences grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 1958Edwards foundedMiles Lowell Edwards starts the company around heart-valve innovation.
- 2000Spin-off public companyEdwards becomes an independent public company.
- 2011U.S. TAVR approvalSAPIEN TAVR launches a major structural-heart market.
- 2024Critical Care separationEdwards narrows focus on structural heart.
- 2025$4.5B TAVR salesFull-year TAVR sales grow 8.6% constant currency.
- 2026Sales growth guidanceEdwards guides to continued 2026 sales growth.
Who are Edwards Lifesciences's competitors?
Edwards Lifesciences competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- MedtronicCompetes in structural heart, cardiovascular devices, and hospital accounts.
- AbbottCompetes in structural heart, cardiac rhythm, and hospital device relationships.
- Boston ScientificCompetes in interventional cardiology and structural-heart-adjacent procedures.
- Johnson & Johnson MedTechCompetes in hospital devices, surgery, and enterprise procurement.
- ArtivionCompetes in cardiac and vascular surgical technologies.
- StrykerCompetes for hospital capital, OR workflows, and medtech procurement attention.
Edwards Lifesciences — frequently asked questions
